Pann-Ghill Suh
Pann-Ghill Suh, Pohang-City KR
Patent application number | Description | Published |
---|---|---|
20090118197 | Immune-Modulating Peptide - Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or neutrophils in vitro; that induce degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; that stimulate extracellular signal regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; or that stimulate Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1. | 05-07-2009 |
20100120662 | Glucose uptake modulator and method for treating diabetes or diabetic complications - The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator. | 05-13-2010 |
20100291089 | LIGAND OF REGULATING IMMUNE RESPONSE, AND USE THEREOF IN TREATING AN IMMUNE RESPONSE-RELATED DISEASE - The present invention relates to a ligand to regulate immune response, i.e., PACAP27 which is one of pituitary adenylate cyclase-activating polypeptides and Serum amyloid A (SAA), and their novel use in treating or preventing diseases associated with immune response. More specifically, the present invention relates to a complex of PACAP27-FPRL1 having a regulatory effect on immune response, and a use thereof in regulating immune response. In another aspect, the present invention relates to a complex of SAA and FPRL1, and a use thereof in inhibiting synoviocyte hyperplasia and angiogenesis and treating or preventing inflammatory diseases including Rheumatoid arthritis (RA). | 11-18-2010 |
Pann-Ghill Suh, Pohang KR
Patent application number | Description | Published |
---|---|---|
20090304667 | Method of Regulating Mammalian Target-of-Rapamycin Activity by Interaction Between Phospholipase D and RHEB - The present invention relates to method of regulating mammalian target-of-rapamycin (mTOR) based on a novel finding of a regulating mechanism of mTOR by a phospholipase D (PLD), and Ras homolog enriched in brain (Rheb). Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibitin mTOR. | 12-10-2009 |
20100184636 | Method of Regulating Mammalian Target-of-Rapamycin Activity by Interaction Between Phospholipase D and Raptor - The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR. | 07-22-2010 |
Pann-Ghill Suh, Kyungsangbuk-Do KR
Patent application number | Description | Published |
---|---|---|
20080207490 | Glucose Uptake Modulator and Method for Treating Diabetes or Diabetic Complications - The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator. | 08-28-2008 |
20080274978 | Peptides That Antagonize Fpr Class Receptor Mediated Signaling - The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity. | 11-06-2008 |
20090312250 | EPIDERMAL GROWTH FACTOR INCREASING INSULIN SECRETION AND LOWERING BLOOD GLUCOSE - The present inventors show that a brief exposure to EGF stimulates insulin secretion glucose-independently via a Ca2+ influx- and PLD2-dependent mechanism. Furthermore, the present invention shows that EGF is a novel secretagogue that lowers plasma glucose levels in normal and diabetic mice, suggesting the potential for EGF treatment in diabetes. | 12-17-2009 |
Pann-Ghill Suh, Pohang-Si KR
Patent application number | Description | Published |
---|---|---|
20130039918 | Pharmaceutical Composition Using Connective-tissue Growth Factor - This disclosure relates to an angiogenesis-related pharmaceutical composition using connective tissue growth factor, more particularly to a pharmaceutical composition for promoting angiogenesis containing the connective tissue growth factor or a pharmaceutical composition for inhibiting angiogenesis containing at least one selected from the group consisting of polypeptide, antibody and a compound binding to connective tissue growth factor. The fragment of connective tissue growth factor protein, which was found out in the present invention, is a binding region to FPRL1, effectively induces FPRL1-specific ERK phosphorylation, activates FPRL1 to increase intracellular Ca | 02-14-2013 |